OpSens to Present at the Lytham Partners Winter 2021 Investor Conference Presentation at 11 AM (ET), Monday December 13, 2021
OPSENS TO PRESENT AT THE LYTHAM PARTNERS WINTER 2021 INVESTOR CONFERENCE
Presentation at 11 AM (ET), Monday December 13, 2021
Quebec, Quebec, December 7, 2021 – OpSens inc. («OpSens» or the «Company») (TSX:OPS) (OTCQX:OPSSF), a medical device cardiology-focused company delivering innovative solutions based on its proprietary optical technology, announced today that it will be participating in the Lytham Partners Winter 2021 Investor Conference taking place from December 13-16, 2021. During the event, the Company will be participating in a webcasted Fireside Chat, discussing its vision for 2022 and conducting 1×1 virtual investor meetings.
The webcasted Fireside Chat will be available for viewing on Monday, December 13, at 11 AM ET on OpSens’ website at www.opsens.com or https://wsw.com/webcast/lytham3/ops.to/2315750. The webcast will be archived and available for replay following the live event.
Management will also be participating in virtual one-on-one meetings throughout the event, which runs from December 13-16, 2021. To arrange a meeting, please contact a Lytham Partners representative at or register at www.lythampartners.com/winter2021invreg.
About OpSens Inc. (www.OpSens.com or www.OpSensmedical.com)
OpSens focuses mainly in interventional cardiology. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and excellent lesions access. The OptoWire has been used in the diagnosis and treatment of over 150,000 patients in more than 30 countries. It is approved for sale in the United States, European Union, Japan, and Canada.
OpSens is also involved in industrial activities in developing, manufacturing, and installing innovative fiber optic sensing solutions for critical applications.
For further information, please contact:
Louis Laflamme, CPA, CA, Chief Executive Officer, 418.781.0333
Robin Villeneuve, CPA, CA Chief Financial Officer, 418.781.0333